HCC: Highlights from ILCA and ESMO 2021

December 06, 2023 00:13:19
HCC: Highlights from ILCA and ESMO 2021
COR2ED - Oncology Medical Conversation
HCC: Highlights from ILCA and ESMO 2021

Dec 06 2023 | 00:13:19

/

Show Notes

Professor Matthias Pinter, medical hepatologist from the medical University of Vienna in Austria shares some insights from key abstracts and topics discussed at ILCA 2021 and ESMO 2021 in hepatocellular carcinoma.

One main topic included discussions about treatment options in first-line systemic therapy and managing patients who still may need to receive a TKI in first-line instead. Another topic covered is how to proceed with immunotherapy in HCC, in particular the rationale for triplet immunotherapy combination.

There were two studies data presented on atezolizumab plus bevacizumab, the new reference standard of care in systemic front-line HCC treatment.

Another interesting topic was the combination of TACE with immune checkpoint blockade in intermediate stage HCC.

Regarding monotherapy TKI in first-line setting, Prof Pinter points out that around 15 to 20% of HCC patients are not ideal candidates for atezolizumab plus bevacizumab, and these are mainly patients with HCC recurrence of the liver transplantations, patients with severe autoimmune disease, or those with a high bleeding risk.

He discusses several real-world evidence studies including lenvatinib, sorafenib and regorafenib in special populations that are usually excluded from clinical trials.

 Prof Pinter also discusses data presented covering predictive and prognostic biomarkers such as cachexia, the growing role of AI, multibipolar radiofrequency ablation and the potential role of underlying etiology as a predictor of the efficacy of immunotherapy.

Other Episodes

Episode

January 07, 2025 00:20:19
Episode Cover

Intermediate HCC – treatment options and strategies

In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr...

Listen

Episode

December 06, 2023 00:30:42
Episode Cover

HCC: VEGFR-TKI monotherapy for unresectable or advanced HCC in 1st line setting

Prof. Josep Llovet and Prof. Stephen L. Chan discuss a very interesting topic about the use of the VEGFR TKIs monotherapy in the treatment...

Listen

Episode

December 06, 2023 00:19:56
Episode Cover

Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3

In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on...

Listen